Grove Bank & Trust’s Mereo BioPharma MREO Stock Holding History

Grove Bank & Trust’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12	Closed	-$27	–	888
2025 Q1	$27	Buy	+12	New	+$34	﹤0.01%	843

Other funds holding MREO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Grove Bank & Trust's MREO Position: Q2 2025 in Review

Grove Bank & Trust sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 12 shares — an estimated $27 sold.

Grove Bank & Trust first reported a position in MREO in Q1 2025 and held it in 1 quarter. The position peaked at $27 in Q1 2025. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

Grove Bank & Trust reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
Grove Bank & Trust sold 12 Mereo BioPharma shares in Q2 2025, an estimated $27.
Grove Bank & Trust first reported a position in Mereo BioPharma in Q1 2025 and held it in 1 quarter.
Grove Bank & Trust's Mereo BioPharma position peaked at $27 in Q1 2025.
86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on Grove Bank & Trust's 13F filing for Q2 2025, filed 11 Jul 2025.